From the Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong, China.
J Biol Chem. 2013 Oct 11;288(41):29923-33. doi: 10.1074/jbc.M113.483909. Epub 2013 Aug 28.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis and kills cancer cells but not normal cells. However, TRAIL resistance due to low level of TRAIL receptor expression is widely found in cancer cells and hampers its development for cancer treatment. Thus, the agents that can sensitize the tumor cells to TRAIL-mediated apoptosis are urgently needed. We investigated whether tanshinones, the major bioactive compounds of Salvia miltiorrhiza (danshen), can up-regulate TRAIL receptor expression. Among the major tanshinones being tested, cryptotanshinone (CT) showed the best ability to induce TRAIL receptor 2 (DR5) expression. We further showed that CT was capable of promoting TRAIL-induced cell death and apoptosis in A375 melanoma cells. CT-induced DR5 induction was not cell type-specific, as DR5 induction was observed in other cancer cell types. DR5 knockdown abolished the enhancing effect of CT on TRAIL responses. Mechanistically, induction of the DR5 by CT was found to be p53-independent but dependent on the induction of CCAAT/enhancer-binding protein-homologous protein (CHOP). Knockdown of CHOP abolished CT-induced DR5 expression and the associated potentiation of TRAIL-mediated cell death. In addition, CT-induced ROS production preceded up-regulation of CHOP and DR5 and consequent sensitization of cells to TRAIL. Interestingly, CT also converted TRAIL-resistant lung A549 cancer cells into TRAIL-sensitive cells. Taken together, our results indicate that CT can potentiate TRAIL-induced apoptosis through up-regulation of DR5.
肿瘤坏死因子相关凋亡诱导配体(TRAIL)选择性地诱导凋亡并杀死癌细胞而不杀死正常细胞。然而,由于 TRAIL 受体表达水平低,导致 TRAIL 抵抗在癌细胞中广泛存在,这阻碍了其在癌症治疗中的发展。因此,迫切需要能够使肿瘤细胞对 TRAIL 介导的凋亡敏感的药物。我们研究了丹参的主要生物活性化合物丹参酮是否可以上调 TRAIL 受体的表达。在所测试的主要丹参酮中,隐丹参酮(CT)显示出最强的诱导 TRAIL 受体 2(DR5)表达的能力。我们进一步表明,CT 能够促进 A375 黑色素瘤细胞中 TRAIL 诱导的细胞死亡和凋亡。CT 诱导的 DR5 诱导不是细胞类型特异性的,因为在其他癌细胞类型中也观察到 DR5 诱导。DR5 敲低消除了 CT 对 TRAIL 反应的增强作用。在机制上,发现 CT 诱导的 DR5 不依赖于 p53,而是依赖于 CCAAT/增强子结合蛋白同源蛋白(CHOP)的诱导。CHOP 敲低消除了 CT 诱导的 DR5 表达和 TRAIL 介导的细胞死亡的相关增强作用。此外,CT 诱导的 ROS 产生先于 CHOP 和 DR5 的上调,并随后使细胞对 TRAIL 敏感。有趣的是,CT 还将 TRAIL 耐药的肺癌 A549 癌细胞转化为 TRAIL 敏感细胞。总之,我们的结果表明 CT 可以通过上调 DR5 来增强 TRAIL 诱导的凋亡。